TSPY22P

Across TCGA pan-cancer cohorts, TSPY22P RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated TSPY22P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TSPY22P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPY22P expression acts as an unfavorable survival marker.

LIHC, SKCM, and ESCA are the cancer types where TSPY22P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.118	0.569	<.001	108	view →
SKCM	OS	Tertile	All	0.402	0.793	<.001	36	view →
ESCA	DFS	Tertile	III,IV	0.122	0.448	.005	18	view →
LUAD	DFS	Tertile	IV	0.333	0.671	.048	18	view →
LUSC	OS	Tertile	All	0.150	0.411	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TSPY22P–LIHC (DFS)

Open the LIHC breakdown →